DT

DTx Pharma is a biotechnology company specializing in the development of RNA-based therapeutics using its proprietary FALCON platform. The company's technology utilizes fatty acid ligands conjugated to oligonucleotides to enhance the delivery and uptake of siRNA into tissues beyond the liver, specifically targeting the peripheral nervous system and other extra-hepatic tissues. Its lead program, DTX-1252, is designed to treat Charcot-Marie-Tooth disease type 1A (CMT1A) by suppressing the overproduction of PMP22. In July 2023, the company was acquired by Novartis to bolster its RNA medicine pipeline and expand its capabilities in neuromuscular and neurological diseases.